Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy

Clinical Infectious Diseases

Volumn 55, Issue 2, 2012, Pages 169-177

  Pasipanodya, Jotam G ^a   Srivastava, Shashikant ^a   Gumbo, Tawanda ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; DRUG ACETYLATION; DRUG TREATMENT FAILURE; EFFECT SIZE; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SPUTUM; SYSTEMATIC REVIEW; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; ISONIAZID; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SPUTUM; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84864153386     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis353     Document Type: Review

References (34)

1. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3:S231-79. (Pubitemid 29481843)
2. Visser ME, Grewal HM, Swart EC, et al. The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial. Am J Clin Nutr 2011; 93:93-100.
3. Hesseling AC, Walzl G, Enarson DA, et al. Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int J Tuberc Lung Dis 2010; 14:560-70.
4. MacKenzie WR, Heilig CM, Bozeman L, et al. Geographic differences in time to culture conversion in liquid media: tuberculosis trials consortium study 28. Culture conversion is delayed in Africa. PLoS One 2011; 6:e18358.
5. World Health Organization. Global tuberculosis control: WHO report 2011. Available at: http://www.who.int/tb/publications/global-report/2011/gtbr11-full. pdf. Accessed 7 February 2012.
6. Calver AD, Falmer AA, Murray M, et al. Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis 2010; 16:264-71.
7. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrugresistant tuberculosis not due to noncompliance but to betweenpatient pharmacokinetic variability. J Infect Dis 2011; 204:1951-9.
8. Srivastava S, Sherman C, Meek C, Leff R, Gumbo T. Pharmacokinetic mismatch does not lead to emergence of isoniazid-or rifampinresistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling. Antimicrob Agents Chemother 2011; 55:5085-9.
9. Dartois V. Drug forgiveness and interpatient pharmacokinetic variability in tuberculosis. J Infect Dis 2011; 204:1827-9.
10. Evans DA, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. Br Med J 1960; 2:485-91.
11. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother 2005; 49:1733-8. (Pubitemid 40631582)
12. Pasipanodya J, Gumbo T. An oracle: antituberculosis pharmacokineticspharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. Antimicrob Agents Chemother 2011; 55:24-34.
13. Gumbo T, Louie A, Liu W, et al. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother 2007; 51:2329-36. (Pubitemid 47047307)
14. Jayaram R, Shandil RK, Gaonkar S, et al. Isoniazid pharmacokineticspharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2004; 48:2951-7. (Pubitemid 38989160)
15. Ellard GA. The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis. Tubercle 1984; 65:211-27. (Pubitemid 14027721)
16. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement. PLoS Med 2009; 6:e1000097.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-88. (Pubitemid 17189972)
18. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-34. (Pubitemid 27387172)
19. Tuberculosis Chemotherapy Center, Madras. A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis. Bull World Health Organ 1970; 43:143-206.
20. Anonymous. Ethambutol plus isoniazid for the treatment of pulmonary tuberculosis: a controlled trial of our regimens. Tubercle 1981; 62:13-29.
21. Weiner M, Burman W, Vernon A, et al. Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. Am J Respir Crit Care Med 2003; 167: 1341-7. (Pubitemid 36609717)
22. Anonymous. A controlled comparison of two fully supervised onceweekly regimens in the treatment of newly diagnosed pulmonary tuberculosis. Tubercle 1973; 54:23-45.
23. Tam CM, Chan SL, Kam KM, et al. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Interim report: no activity of isoniazid in the continuation phase. Int J Tuberc Lung Dis 2000; 4:262-7. (Pubitemid 30151576)
24. Anonymous. Controlled trial of 6-and 9-month regimens of daily and intermittent streptomycin plus isoniazid plus pyrazinamide for pulmonary tuberculosis in Hong Kong. Tubercle 1975; 56:81-96.
25. Selkon JB, Fox W, Gangadharam PR, Ramachandran K, Ramakrishnan CV, Velu S. Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. 2. Clinical implications in the treatment of pulmonary tuberculosis with isoniazid either alone or in combination with PAS. Bull World Health Organ 1961; 25:779-92.
26. British Medical Research Council. Co-operative controlled trial of a standard regimen of streptomycin, PAS and isoniazid and three alternative regimens of chemotherapy in Britain: a report from the British Medical Research Council. Tubercle 1973; 54:99-129.
27. Anonymous. A pilot study of two regimens of intermittent thiacetazone plus isoniazid in the treatment of pulmonary tuberculosis in East Africa. Tubercle 1974; 55:211-21.
28. Anonymous. Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore. The results up to 30 months. Am Rev Respir Dis 1977; 116:807-20.
29. Anonymous. A study of two twice-weekly and a once-weekly continuation regimen of tuberculosis chemotherapy, including a comparison of two durations of treatment. 2. Second report: the results at 36 months. Tubercle 1977; 58:129-36.
30. Anonymous. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. East African-British Medical Research Councils. Lancet 1974; 2:237-40.
31. Anonymous. Controlled comparison of oral twice-weekly and oral daily isoniazid plus PAS in newly diagnosed pulmonary tuberculosis. Br Med J 1973; 2:7-11.
32. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006; 50:1170-7.
33. Copeland KT, Checkoway H, McMichael AJ, Holbrook RH. Bias due to misclassification in the estimation of relative risk. Am J Epidemiol 1977; 105:488-95. (Pubitemid 8112070)
34. Chigutsa E, Visser ME, Swart EC, et al. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampicin concentrations: dosing implications. Antimicrob Agents Chemother 2011; 55:4122-7.